23.10.2015 19:15:00

AbbVie Inc. -- Moody's: Viekira warnings credit negative for AbbVie

New York, October 23, 2015 -- Moody's Investors Service commented that new warnings by the US Food and Drug Administration (FDA) on AbbVie's hepatitis C drug Viekira Pak are credit negative because of lower sales potential. There is no impact on AbbVie's Baa1 ratings at this time, and the rating outlook remains negative.

Vollständigen Artikel bei Moodys lesen